Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Genetic characteristics of patients responsive to Ranibizumab but Resistant to Aflibercept
研究概览
简要总结
A cohort of patients responsive to treatment with ranibizumab but resistant to
aflibercept were identified in a previously conducted retrospective study. Identified
patients will have their blood drawn for genome wide sequencing. The sequencing
data will be compiled and analyzed in an attempt to identify a common genetic basis
for patients susceptible to ranibizumab but resistant to aflibercept.
详细描述
A cohort of patients responsive to treatment with ranibizumab but resistant to
aflibercept were identified in a previously conducted retrospective study. Identified
patients will have their blood drawn for genome wide sequencing. The sequencing
data will be compiled and analyzed in an attempt to identify a common genetic basis
for patients susceptible to ranibizumab but resistant to aflibercept.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects will be eligible if the following criteria are met:
- •Demonstrate worsening of exudation when switched from ranibizumab to aflibercept
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
排除标准
- •Any other condition that the investigator believes would pose a significant hazard to the subject
研究组 & 干预措施
Neovascular ARMD Patients
Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
干预措施: Ranibizumab (Drug)
Neovascular ARMD Patients
Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
干预措施: Aflibercept (Drug)
结局指标
主要结局
Genetic characteristics of patients responsive to Ranibizumab but Resistant to Aflibercept
时间窗: 1 day
To determine a genetic basis for patients responsive to ranibizumab but resistant to aflibercept.
次要结局
未报告次要终点